Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the  weeks prior to the initiation of study drug.
Biologic (anti-neoplastic agent): patients must be at least  days since the completion of therapy prior to registration
Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy
Concomitant treatment with other anti-neoplastic agents (hormonal therapy acceptable)
Biologic (anti-neoplastic agent): at least  days since the completion of therapy with a biological agent
Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the  weeks prior to the initiation of study drug administration.
Treatment with any local or systemic anti-neoplastic therapy, radiotherapy (excluding limited palliative radiation), or investigational anticancer agent within  days or  halflives, whichever is longer, up to a maximum wash-out period of  days prior to the initiation of study drug administration
Concurrent therapy with other systemic anti-neoplastic or investigational agents
No other investigational anti-neoplastic therapy for one month prior to entry in this study
No other investigational anti-neoplastic therapy for one month prior to entry in this study
Other anti-neoplastic investigational agents currently or within  weeks prior to apheresis (i.e. start of protocol therapy)
Patients may not be receiving any other anti-neoplastic investigational agents
Concomitant treatment with other anti-neoplastic agents, with the exception, when clinically indicated, of prophylaxis in the post-transplantation setting with intrathecal chemotherapy
Subject has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within  days prior to first dose of study drug
Other anti-neoplastic investigational agents currently or within  days prior to apheresis (i.e. start of protocol therapy)
Biologic (anti-neoplastic agent)
Prior, concomitant or planned treatment with Novo-TTF, EGFR-targeted therapy, bevacizumab, Gliadel wafers or other intratumoral or intracavity anti-neoplastic therapy
Biological (anti-neoplastic) therapy: ?  days prior to screening.
Patients may not be receiving any other anti-neoplastic agents
Fewer than  days before Cycle  Day  since administration of hormonal or biological anti-neoplastic agents
Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within  weeks prior to starting treatment
Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents
Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents
A biologic agent (i.e., monoclonal antibodies) for anti-neoplastic intent within  days
Steroid therapy for anti-neoplastic intent within  days
Patients who are currently receiving and responding to a different course of anti-neoplastic therapy, within the limits of acceptable toxicity per standard clinical practice, may not be enrolled to this study
Receipt of the following treatment prior to first dose of BGB-: corticosteroids given with anti-neoplastic intent within  days, chemotherapy or radiotherapy within  weeks, monoclonal antibody within  weeks.
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within  weeks of starting study treatment with sonidegib
Is currently participating and receiving study therapy with potential anti-neoplastic activity, or has participated in a study of an investigational agent and received study therapy with potential anti-neoplastic activity within  weeks of the first dose of treatment
? weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agents
Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy
Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the  weeks prior to the initiation of study drug.
Patients under treatment (or who will have recently been treated) with anti-neoplastic, immunosuppressive or hormonal medications
Other anti-neoplastic investigational agents currently or within  days prior to apheresis (i.e. start of protocol therapy)
Monoclonal antibody (mAb) for direct anti-neoplastic treatment within  weeks
Patients with no more than  prior treatments with systemic anti-neoplastic therapy for CCA.
> previous systemic anti-neoplastic regimens for CCA.
Received anti-neoplastic monoclonal antibodies within  days of the first dose of study drug.
Anti-neoplastic agents
Participants cannot have received any anti-neoplastic therapy (including radiotherapy, chemotherapy or immunotherapy) after ASCT
Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents
Concomitant use of additional anti-neoplastic agents will not be allowed in this study
Must not have received systemic anti-neoplastic therapy, including radiotherapy within  days of study treatment
Patients receiving other anti-neoplastic agents are excluded
Concurrent treatment with other investigational or anti-neoplastic agents
Anti-neoplastic treatment less than  weeks prior to enrollment, with the exception of hydroxyurea
Patient may not receive concomitant cytotoxic anti-neoplastic therapy during treatment; patients may be allowed to use hormonal suppression therapy or bisphosphonates for hypercalcemia
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently
Subject has received a monoclonal antibody for anti-neoplastic intent within  weeks prior to the first dose of study drug.
Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents
Last dose of systemic anti-neoplastic therapy >  days prior to first RO infusion
Concomitant treatment with other anti-neoplastic agents, with the exception of hydroxyurea
Current receiving any other anti-neoplastic investigational agents
Biologic/Immunologic (anti-neoplastic) therapy: It must be at least  days since the completion of therapy with a biologic/immunologic agent such as a monoclonal antibody prior to study enrollment and at least  days since non-study chemotherapy has been administered, excluding CNS directed therapy as described in Section ..
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within  weeks of starting LDE
Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents
Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
Patient has concurrent use of anti-neoplastic agents including investigational therapy
Subject has received a biologic agent for anti-neoplastic intent within  days prior to the first dose of study drug
Biologic (anti-neoplastic agent including retinoids): Last dose given at least  days prior to the start date for protocol therapy.
Biologic agent (i.e., antibodies) for anti-neoplastic intent within  days
Steroid therapy for anti-neoplastic intent within  days
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy, or radiotherapy) concurrently or within  weeks of starting treatment
Concurrent therapy with other anti-neoplastic or experimental agents
The subject is receiving concomitant radiotherapy, chemotherapy, other anti-neoplastic therapy, or investigational therapy (other than the investigational therapy under study)
The subject has received radiation therapy, chemotherapy, other anti-neoplastic therapy, or investigational therapy within  days prior to first dose of study drug
Biologic (anti-neoplastic) agent: At least  days since the completion of therapy with a biologic agent; at least  half-lives since previous monoclonal antibody therapy
All previous treatment (including surgery, radiotherapy and systemic anti-neoplastic therapy) must have been completed at least three weeks prior to study entry and any acute toxicities must have resolved
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within  weeks of starting treatment with LDE
Patients currently using anti-neoplastic or anti-tumor agents, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy
Treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the  weeks prior to study drug administration
Subjects must have neurological findings (i.e. loss of consciousness, paresis, cranial neuropathy, etc.), and/or radiological abnormalities in the brain (neoplastic or non-neoplastic in nature)
 weeks since any oral anti-neoplastic or oral investigational agent
Biologic: ? days from anti-neoplastic biologic agent